Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value
$305.23−0.45 (-0.15%)
Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –
Krystal Biotech profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Krystal Biotech's profit margin for the twelve months ending Sep 30, 2026 was 47.9%. For fiscal 2025 it was 52.6%, against 30.7% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.6% | +21.9 |
| FY2024 | Dec 31, 2024 | 30.7% | +9.1 |
| FY2023 | Dec 31, 2023 | 21.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 49.5% | −31.6 |
| Q2 FY2026 | Jun 30, 2026 | 45.9% | +6.0 |
| Q1 FY2026 | Mar 31, 2026 | 48.1% | +7.5 |
| Q4 FY2025 | Dec 31, 2025 | 48.0% | −1.9 |
| Q3 FY2025 | Sep 30, 2025 | 81.2% | +48.7 |
| Q2 FY2025 | Jun 30, 2025 | 39.9% | +17.8 |
| Q1 FY2025 | Mar 31, 2025 | 40.5% | +38.5 |
| Q4 FY2024 | Dec 31, 2024 | 49.9% | +29.3 |
| Q3 FY2024 | Sep 30, 2024 | 32.4% | −911.3 |
| Q2 FY2024 | Jun 30, 2024 | 22.2% | – |
| Q1 FY2024 | Mar 31, 2024 | 2.1% | – |
| Q4 FY2023 | Dec 31, 2023 | 20.6% | – |
| Q3 FY2023 | Sep 30, 2023 | 943.7% | – |
See a number that looks wrong?